Of Counsel Brue Keyes was quoted in a Milwaukee Journal Sentinel article, “Bublr voices support for Bird and asks state to legalize,” about the rollout of the electric scooter-sharing program Bird in Milwaukee.
Keyes, board president and co-founder of the greater Milwaukee bike-sharing program Bublr Bikes, emphasized the similarities between the two companies, which both provide transportation alternatives to cars. “While I would rather see people on bikes, I do think electric scooters accomplish the same goals we’re trying to accomplish – they’re easy to get around with, and they go that first or last mile,” he said.
Keyes, board president and co-founder of the greater Milwaukee bike-sharing program Bublr Bikes, emphasized the similarities between the two companies, which both provide transportation alternatives to cars. “While I would rather see people on bikes, I do think electric scooters accomplish the same goals we’re trying to accomplish – they’re easy to get around with, and they go that first or last mile,” he said.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”